Patient engagement as important as the data
25 February 2015
The thought of having unfettered access to all the medical and genomic data of a million Americans had researchers gathered at the National Institutes of Health’s first workshop on precision medicine licking their lips.
India mulling plans to build bulk drug manufacturing capacity
25 February 2015
The government will shortly come out with strategies to improve bulk drug manufacturing capacity in India in order to reduce dependence on China for import of bulk drugs.
24 February 2015
Epic Sciences announced today that results from studies in metastatic castration resistant prostate cancer (mCRPC), neuroendocrine prostate cancer (NEPC) and muscle-invasive, metastatic bladder cancers using Epic's circulating tumor cell (CTC) technology will be presented at the 2015 ASCO Genitourinary Cancers Symposium which will be held February 26 to 28 at Rosen Shingle Creek in Orlando, Fla.
Big Data digging yields unprecedented road map of the epigenome
24 February 2015
A massive data generation and analysis program has uncovered a map of the epigenome, the switches that turn genes off and on. Researchers published their findings in a series of papers in Nature and released the data for further analysis through the National Center for Biotechnology Information.
FDA Sets Policies to Enhance Drug Security and Safety
24 February 2015
FDA Center for Drug Evaluation and Research (CDER) director Janet Woodcock’s top priorities for 2015 are to establish new rules to ensure safe drug compounding, while also implementing a new track-and-trace system for monitoring drugs and ingredients moving through the pharmaceutical supply chain.
Ten Years of Therapeutic Venture Capital Inside BIO Industry Analysis
24 February 2015
What therapeutic areas have received the most funding in private drug companies over the last decade? How much of this has been for new drugs vs drug delivery? How much into biologics vs small molecules?
Pharma's top 10 M&A deals of 2014
20 February 2015
2014 was quite the banner year for pharma M&A. According to EY's annual firepower report, deals topped $200 billion--well over twice the average volume from over the past decade.
NIH-supported researchers map epigenome of more than 100 tissue and cell types
20 February 2015
Much like mapping the human genome laid the foundations for understanding the genetic basis of human health, new maps of the human epigenome may further unravel the complex links between DNA and disease. The epigenome is part of the machinery that helps direct how genes are turned off and on in different types of cells.
The 2014 Numbers Are In: FDA’s Orphan Drug Program Shatters Records
20 February 2015
FDA’s agency-wide performance management system, known as FDA-TRACK, provides some information on orphan drug designations and approvals, that system is not up-to-date. So we have to get our data from other sources – primarily (though not exclusively) from FDA’s Orphan Drug Designations and Approvals database.
Artificial heart sees most patients to donor heart within a few years
20 February 2015
Artificial, mechanical hearts are effective in getting almost three-quarters of patients to a donor heart transplant, recent data on the SynCardia Total Artificial Heart suggest. But that feat doesn't contain SynCardia's ambitions--it recently started a trial for permanent use of its artificial heart that's ultimately designed for FDA submission.
06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
87% of cancer patients give positive ratings for medical care quality
18 September 2024
The Russian market of fillers and biorevitalizers grew by 21% in the first half of 2024
18 September 2024
Pharma’s Patient Reach Problem: Billions Still Left Behind
17 September 2024
17 September 2024